Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
Saved in:
| Published in | Diabetes & metabolism Vol. 46; no. 2; pp. 100 - 109 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
01.04.2020
|
| Online Access | Get full text |
Cover
Loading…
| Author | Janez, A. Capehorn, M.S. Catarig, A.-M. Tadayon, S. Marre, M. Furberg, J.K. Price, H.C. Vergès, B. |
|---|---|
| Author_xml | – sequence: 1 givenname: M.S. orcidid: 0000-0002-8196-2505 surname: Capehorn fullname: Capehorn, M.S. – sequence: 2 givenname: A.-M. surname: Catarig fullname: Catarig, A.-M. – sequence: 3 givenname: J.K. surname: Furberg fullname: Furberg, J.K. – sequence: 4 givenname: A. surname: Janez fullname: Janez, A. – sequence: 5 givenname: H.C. surname: Price fullname: Price, H.C. – sequence: 6 givenname: S. surname: Tadayon fullname: Tadayon, S. – sequence: 7 givenname: B. surname: Vergès fullname: Vergès, B. – sequence: 8 givenname: M. surname: Marre fullname: Marre, M. |
| BookMark | eNp9kL9OwzAQxj0UiRZ4A4YbYUjx2WlI2KqKP5UqGGjnyLXPxSVNqtgFZeMdeBDeiSchJQyIgemku9939903YL2yKomxU-RD5JhcrIfGqSWFoeCY7VuIlz3WR5GISCYyOWQD79eco8hk2mcf19Y6rXQDqjTglaXQQGWhKjVFr0TPRQOeNmpV7IIzBDjksFnBi-8Io1wLFK7-BYg9oDwoY6KqhFABfr69S6hqVbRXWurboNNg6t3KgyvB75Zr0sHDqwtPEJotgYAOIw9nj4vH-Xh6D8jPj9mBVYWnk596xBY31_PJXTR7uJ1OxrNIixGGKDZJqiQRR65kmmVLSpKlMFLZkTRpO9UZxsjJxlIg6pGNtRSpSk3MdRILLY_YVbdX15X3Ndlcu6CCq8pQtz_nyPN93Pk672zm-7jzLu5WHP8Rb2u3UXXzv-wLEqKLIA |
| CitedBy_id | crossref_primary_10_1507_endocrj_EJ21_0129 crossref_primary_10_3390_ijms23084334 crossref_primary_10_1016_j_eprac_2023_11_007 crossref_primary_10_2337_cd19_0100 crossref_primary_10_1016_j_endien_2021_11_031 crossref_primary_10_1111_imj_16126 crossref_primary_10_1007_s40265_023_01982_6 crossref_primary_10_1111_dom_15888 crossref_primary_10_1136_bmjdrc_2021_002619 crossref_primary_10_1007_s12325_020_01337_7 crossref_primary_10_1056_NEJMoa2028395 crossref_primary_10_1097_QAD_0000000000003791 crossref_primary_10_1016_j_diabres_2021_108931 crossref_primary_10_1007_s00125_019_05065_8 crossref_primary_10_1016_j_lfs_2024_123328 crossref_primary_10_2337_dc23_1070 crossref_primary_10_1007_s11695_023_06484_8 crossref_primary_10_7759_cureus_38379 crossref_primary_10_2337_dbi21_0004 crossref_primary_10_1016_j_dsx_2023_102834 crossref_primary_10_1186_s13098_023_01195_7 crossref_primary_10_4254_wjh_v15_i4_477 crossref_primary_10_3390_ijms26031094 crossref_primary_10_3389_fnins_2022_824054 crossref_primary_10_62751_2713_0177_2024_5_1_04 crossref_primary_10_1007_s13300_021_01010_4 crossref_primary_10_5937_arhfarm74_50561 crossref_primary_10_3390_healthcare9091125 crossref_primary_10_1007_s40262_024_01449_1 crossref_primary_10_3390_biomedicines10102365 crossref_primary_10_1007_s40200_023_01341_y crossref_primary_10_1055_a_2007_2061 crossref_primary_10_33805_2576_8484_190 crossref_primary_10_3390_jcm11174938 crossref_primary_10_2147_DDDT_S365416 crossref_primary_10_1007_s40200_021_00899_9 crossref_primary_10_2217_cer_2021_0016 crossref_primary_10_1111_dom_14892 crossref_primary_10_36469_001c_124111 crossref_primary_10_3390_biomedicines13030728 crossref_primary_10_1016_j_jdiacomp_2023_108529 crossref_primary_10_3892_etm_2021_10601 crossref_primary_10_4236_ijcm_2022_131002 crossref_primary_10_15557_PiMR_2024_0023 crossref_primary_10_1186_s12933_023_02051_8 crossref_primary_10_1111_1753_0407_70000 crossref_primary_10_1016_j_endinu_2025_501574 crossref_primary_10_1038_s41574_024_00979_9 crossref_primary_10_1111_resp_14545 crossref_primary_10_20517_mtod_2024_45 crossref_primary_10_1177_08971900221087127 crossref_primary_10_1016_j_mmm_2024_11_008 crossref_primary_10_2106_JBJS_RVW_23_00167 crossref_primary_10_1016_j_dsx_2022_102511 crossref_primary_10_1080_17512433_2023_2174099 crossref_primary_10_1111_cts_70127 crossref_primary_10_1093_cvr_cvae120 crossref_primary_10_1159_000526808 crossref_primary_10_3390_medicina60030357 crossref_primary_10_1055_a_2492_9440 crossref_primary_10_1007_s13410_020_00878_5 crossref_primary_10_1111_dom_14666 crossref_primary_10_1097_MD_0000000000038236 crossref_primary_10_1093_ckj_sfac096 crossref_primary_10_1016_j_pcd_2023_05_004 crossref_primary_10_1007_s00592_022_01936_6 crossref_primary_10_3389_fendo_2024_1459127 crossref_primary_10_3390_ph18030399 crossref_primary_10_1111_apt_17848 crossref_primary_10_3390_livers3040040 crossref_primary_10_1111_ijcp_13731 crossref_primary_10_1021_acs_jmedchem_4c01242 crossref_primary_10_1080_13543784_2025_2473062 crossref_primary_10_1007_s13300_022_01301_4 crossref_primary_10_1111_dom_14232 crossref_primary_10_1111_dom_14117 crossref_primary_10_1111_jcpt_13224 crossref_primary_10_1007_s13300_023_01515_0 crossref_primary_10_1080_17512433_2024_2363838 crossref_primary_10_1016_j_addr_2020_05_008 crossref_primary_10_1016_j_gastrohep_2020_11_021 crossref_primary_10_1080_17425247_2024_2387110 crossref_primary_10_1016_j_biopha_2020_110708 crossref_primary_10_1016_j_phrs_2023_107031 crossref_primary_10_18087_cardio_2020_9_n1274 crossref_primary_10_1007_s12020_023_03636_9 crossref_primary_10_2174_1871530322666220509225637 crossref_primary_10_1016_j_metabol_2023_155689 crossref_primary_10_23736_S2724_6507_20_03369_6 crossref_primary_10_24304_kjcp_2024_34_1_1 crossref_primary_10_3390_diabetology5010005 crossref_primary_10_1016_j_jdiacomp_2022_108390 crossref_primary_10_20960_nh_05244 crossref_primary_10_1016_j_molmet_2022_101584 crossref_primary_10_1111_jdi_13773 crossref_primary_10_3390_biomedicines10010046 crossref_primary_10_1111_obr_13792 crossref_primary_10_1016_S2213_8587_21_00174_1 crossref_primary_10_1080_14740338_2020_1772230 crossref_primary_10_3389_fendo_2024_1431292 crossref_primary_10_1056_NEJMoa2107519 crossref_primary_10_1080_17512433_2020_1776108 crossref_primary_10_1002_phar_2648 crossref_primary_10_1111_dom_15309 crossref_primary_10_1016_j_diabres_2023_110881 crossref_primary_10_4103_jod_jod_102_22 crossref_primary_10_1016_j_obpill_2023_100098 crossref_primary_10_1093_postmj_qgae148 crossref_primary_10_3389_fendo_2021_645563 crossref_primary_10_14309_ajg_0000000000002519 crossref_primary_10_1038_s41366_024_01499_2 crossref_primary_10_1007_s13410_024_01337_1 crossref_primary_10_1016_j_conctc_2022_100944 crossref_primary_10_1007_s12325_020_01242_z crossref_primary_10_1111_bph_15485 crossref_primary_10_1111_dom_14334 crossref_primary_10_1007_s13300_020_00796_z crossref_primary_10_1016_j_numecd_2022_02_019 crossref_primary_10_1007_s10529_022_03232_3 crossref_primary_10_1186_s12933_022_01585_7 crossref_primary_10_2147_DMSO_S348025 crossref_primary_10_1097_MD9_0000000000000297 crossref_primary_10_1111_apt_17856 crossref_primary_10_3390_ijms24129996 crossref_primary_10_1007_s13300_023_01516_z crossref_primary_10_3390_life13041012 crossref_primary_10_1007_s11154_021_09699_1 crossref_primary_10_1186_s12933_020_01106_4 crossref_primary_10_1016_j_diabres_2025_112086 crossref_primary_10_1111_dom_15554 crossref_primary_10_1111_dom_15794 crossref_primary_10_1016_j_ajem_2024_01_010 crossref_primary_10_1111_dom_14468 crossref_primary_10_1007_s13300_022_01336_7 crossref_primary_10_1007_s11684_021_0873_2 crossref_primary_10_1111_dom_15556 crossref_primary_10_26693_jmbs05_02_036 crossref_primary_10_1007_s11428_021_00733_z crossref_primary_10_1007_s12325_024_03082_7 crossref_primary_10_1016_j_pcd_2021_06_008 crossref_primary_10_1016_j_pharmthera_2025_108824 crossref_primary_10_1093_ckj_sfac069 crossref_primary_10_1111_dom_14582 crossref_primary_10_2147_DDDT_S384884 crossref_primary_10_1016_j_deman_2024_100209 crossref_primary_10_1080_03007995_2024_2322072 crossref_primary_10_3390_nu14122414 crossref_primary_10_1007_s40261_021_01110_w crossref_primary_10_4239_wjd_v14_i4_352 crossref_primary_10_4254_wjh_v16_i5_731 crossref_primary_10_1097_CM9_0000000000002091 crossref_primary_10_1007_s13340_021_00508_3 crossref_primary_10_1007_s00125_024_06144_1 crossref_primary_10_21518_ms2022_010 crossref_primary_10_1007_s11883_022_01027_5 crossref_primary_10_1007_s13300_021_01015_z crossref_primary_10_1007_s12325_022_02385_x crossref_primary_10_1016_j_crphar_2024_100185 crossref_primary_10_3389_fendo_2022_892702 crossref_primary_10_1155_2022_5201684 crossref_primary_10_3390_ijms25084346 crossref_primary_10_1016_j_jdiacomp_2024_108874 crossref_primary_10_1080_17512433_2021_1947796 crossref_primary_10_1007_s12325_024_03000_x crossref_primary_10_1111_dom_16228 crossref_primary_10_23736_S0391_1977_20_03179_X crossref_primary_10_3390_jcm13247732 crossref_primary_10_1007_s00432_025_06154_5 crossref_primary_10_1111_dom_14280 crossref_primary_10_1007_s13300_023_01408_2 crossref_primary_10_31083_j_rcm2507270 crossref_primary_10_3390_diabetology4010011 crossref_primary_10_1001_jama_2021_23619 crossref_primary_10_1016_j_diabres_2023_111018 crossref_primary_10_15829_2713_0177_2023_3_11 crossref_primary_10_1016_j_ijcard_2022_07_017 crossref_primary_10_1093_cvr_cvac112 crossref_primary_10_3390_ijms25031493 crossref_primary_10_1097_JXX_0000000000000661 crossref_primary_10_1111_1744_9987_13651 crossref_primary_10_1177_20451253231165169 crossref_primary_10_1016_S1131_3587_22_00013_9 crossref_primary_10_1080_14656566_2022_2089021 crossref_primary_10_1007_s11883_022_01041_7 crossref_primary_10_3389_fphar_2022_877797 crossref_primary_10_1007_s13300_021_01053_7 crossref_primary_10_1007_s13300_024_01586_7 crossref_primary_10_1097_XCE_0000000000000260 crossref_primary_10_1016_j_eclinm_2024_102782 crossref_primary_10_3390_pharmaceutics15082163 crossref_primary_10_1002_ehf2_14560 crossref_primary_10_1007_s13300_023_01509_y crossref_primary_10_1080_17425255_2024_2401589 crossref_primary_10_1111_acps_13690 crossref_primary_10_1111_dom_14637 crossref_primary_10_1111_dom_14998 crossref_primary_10_1002_pul2_12028 crossref_primary_10_1016_j_clinthera_2023_02_003 crossref_primary_10_1021_acs_jmedchem_1c00565 crossref_primary_10_1007_s40265_024_02029_0 crossref_primary_10_1111_dom_14990 crossref_primary_10_1111_dom_15045 crossref_primary_10_1016_j_rceng_2022_06_001 crossref_primary_10_1016_j_pcd_2020_07_011 crossref_primary_10_3390_nu15030606 crossref_primary_10_1016_j_clinthera_2024_12_014 crossref_primary_10_12998_wjcc_v10_i20_6759 crossref_primary_10_1016_j_freeradbiomed_2024_01_015 crossref_primary_10_3748_wjg_v30_i48_5205 crossref_primary_10_1016_S0140_6736_21_00536_5 crossref_primary_10_1146_annurev_physiol_042222_021346 crossref_primary_10_3389_fendo_2020_00289 crossref_primary_10_1016_j_rce_2022_03_009 crossref_primary_10_1016_j_ekir_2022_07_167 crossref_primary_10_1016_j_mcna_2024_03_002 crossref_primary_10_14341_DM12941 crossref_primary_10_1111_dom_14765 crossref_primary_10_1136_jim_2021_001952 crossref_primary_10_7759_cureus_69008 crossref_primary_10_3389_fphar_2021_695182 crossref_primary_10_1007_s13300_024_01659_7 crossref_primary_10_1080_14656566_2022_2104636 crossref_primary_10_1007_s13300_021_01141_8 crossref_primary_10_1016_j_molmet_2023_101718 crossref_primary_10_1016_j_eclinm_2021_101213 crossref_primary_10_1016_j_endinu_2020_12_004 crossref_primary_10_1007_s10555_024_10192_9 crossref_primary_10_3390_biomedicines11041159 crossref_primary_10_1111_dom_15828 crossref_primary_10_4103_ijdt_ijdt_31_24 crossref_primary_10_1136_bmjdrc_2020_001706 crossref_primary_10_14341_probl13197 crossref_primary_10_3390_ijms24119324 crossref_primary_10_1007_s13340_019_00423_8 crossref_primary_10_3803_EnM_2022_1642 crossref_primary_10_1016_j_clinthera_2020_07_017 crossref_primary_10_1093_asj_sjad240 crossref_primary_10_1111_bph_15647 crossref_primary_10_1007_s13300_020_00984_x crossref_primary_10_1093_ckj_sfab131 crossref_primary_10_3390_nu14214673 crossref_primary_10_1111_nmo_14660 crossref_primary_10_3389_fendo_2021_645617 crossref_primary_10_3390_ijms231911805 crossref_primary_10_3350_cmh_2022_0015 crossref_primary_10_1002_cld_1219 crossref_primary_10_1155_2021_8936865 crossref_primary_10_1007_s11892_023_01530_2 crossref_primary_10_1177_2042018821997320 crossref_primary_10_2337_cd22_0027 crossref_primary_10_3390_jcdd11050145 crossref_primary_10_1016_j_numecd_2021_08_039 crossref_primary_10_4103_jrms_jrms_693_23 crossref_primary_10_1111_dom_15031 crossref_primary_10_36469_jheor_2024_124111 |
| Cites_doi | 10.2337/dc19-S006 10.1016/S2213-8587(17)30013-X 10.1016/S2213-8587(17)30092-X 10.1111/j.1464-5491.1994.tb00316.x 10.1111/dom.12927 10.2337/dc12-2480 10.2337/dc19-S009 10.1007/s00125-018-4729-5 10.1016/S2213-8587(18)30024-X 10.1007/s13300-016-0180-0 10.1007/s00125-012-2534-0 10.1016/S0140-6736(19)31150-X 10.1038/nrendo.2012.140 10.1210/jc.2018-00070 10.1021/acs.jmedchem.5b00726 10.1016/S2213-8587(17)30085-2 10.1016/S0140-6736(12)61267-7 10.1002/bimj.201000239 10.4158/EP15672.GLSUPPL 10.1056/NEJMoa1603827 10.4103/2230-8210.176351 10.1001/jama.2013.281053 10.1056/NEJMoa1616011 10.1056/NEJMoa1607141 10.2337/dc17-0417 10.1007/s00125-014-3460-0 10.1016/S0140-6736(14)60976-4 10.1007/s13300-018-0428-y 10.1016/j.diabet.2017.12.009 10.1007/s13300-018-0424-2 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION |
| DOI | 10.1016/j.diabet.2019.101117 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EndPage | 109 |
| ExternalDocumentID | 10_1016_j_diabet_2019_101117 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO AAYWO AAYXX ABBQC ABMAC ABMZM ABWVN ABXDB ACDAQ ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFCTW AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGRNS AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV CITATION CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OB0 ON- OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SDF SDG SEM SES SJN SPCBC SSH SSZ T5K Z5R ~G- |
| ID | FETCH-LOGICAL-c251t-4d68a3ee010a3899be66b2d3af53d84d6c91410ef43211c5f4c328a8d40c642c3 |
| ISSN | 1262-3636 |
| IngestDate | Thu Jul 03 03:57:12 EDT 2025 Thu Apr 24 22:59:32 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c251t-4d68a3ee010a3899be66b2d3af53d84d6c91410ef43211c5f4c328a8d40c642c3 |
| ORCID | 0000-0002-8196-2505 |
| PageCount | 10 |
| ParticipantIDs | crossref_citationtrail_10_1016_j_diabet_2019_101117 crossref_primary_10_1016_j_diabet_2019_101117 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-04-00 |
| PublicationDateYYYYMMDD | 2020-04-01 |
| PublicationDate_xml | – month: 04 year: 2020 text: 2020-04-00 |
| PublicationDecade | 2020 |
| PublicationTitle | Diabetes & metabolism |
| PublicationYear | 2020 |
| References | Davies (10.1016/j.diabet.2019.101117_bib0185) 2018; 61 Sorli (10.1016/j.diabet.2019.101117_bib0235) 2017; 5 Buse (10.1016/j.diabet.2019.101117_bib0340) 2013; 381 Bretz (10.1016/j.diabet.2019.101117_bib0315) 2011; 53 Aroda (10.1016/j.diabet.2019.101117_bib0250) 2017; 5 Novo Nordisk (10.1016/j.diabet.2019.101117_bib0225) 2018 Ahmann (10.1016/j.diabet.2019.101117_bib0245) 2018; 41 Ahrén (10.1016/j.diabet.2019.101117_bib0240) 2017; 5 Marso (10.1016/j.diabet.2019.101117_bib0190) 2016; 375 Inzucchi (10.1016/j.diabet.2019.101117_bib0285) 2015; 58 Dungan (10.1016/j.diabet.2019.101117_bib0335) 2014; 384 Mann (10.1016/j.diabet.2019.101117_bib0200) 2017; 377 Witkowski (10.1016/j.diabet.2019.101117_bib0330) 2018; 9 Inzucchi (10.1016/j.diabet.2019.101117_bib0280) 2012; 55 Gerstein (10.1016/j.diabet.2019.101117_bib0205) 2019; 394 World Medical Association (10.1016/j.diabet.2019.101117_bib0275) 2013; 310 10.1016/j.diabet.2019.101117_bib0310 Rodbard (10.1016/j.diabet.2019.101117_bib0255) 2018; 103 Pratley (10.1016/j.diabet.2019.101117_bib0260) 2018; 6 Meier (10.1016/j.diabet.2019.101117_bib0210) 2012; 8 Ostawal (10.1016/j.diabet.2019.101117_bib0265) 2016; 7 Lau (10.1016/j.diabet.2019.101117_bib0320) 2015; 58 Kalra (10.1016/j.diabet.2019.101117_bib0215) 2016; 20 Bradley (10.1016/j.diabet.2019.101117_bib0305) 1994; 11 Witkowski (10.1016/j.diabet.2019.101117_bib0325) 2018; 9 Mauricio (10.1016/j.diabet.2019.101117_bib0175) 2017; 19 Novo Nordisk (10.1016/j.diabet.2019.101117_bib0230) 2017 American Diabetes Association (10.1016/j.diabet.2019.101117_bib0180) 2019; (Suppl. 1) 42 10.1016/j.diabet.2019.101117_bib0270 American Diabetes Association (10.1016/j.diabet.2019.101117_bib0290) 2019; 42 Marso (10.1016/j.diabet.2019.101117_bib0195) 2016; 375 Handelsman (10.1016/j.diabet.2019.101117_bib0295) 2015; (Suppl. 1) 21 Seaquist (10.1016/j.diabet.2019.101117_bib0300) 2013; 36 Scheen (10.1016/j.diabet.2019.101117_bib0220) 2018; 44 |
| References_xml | – volume: 42 start-page: S61 year: 2019 ident: 10.1016/j.diabet.2019.101117_bib0290 article-title: 6. Glycemic targets: standards of medical care in diabetes – 2019 publication-title: Diabetes Care doi: 10.2337/dc19-S006 – volume: 5 start-page: 251 year: 2017 ident: 10.1016/j.diabet.2019.101117_bib0235 article-title: Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(17)30013-X – volume: 5 start-page: 341 year: 2017 ident: 10.1016/j.diabet.2019.101117_bib0240 article-title: Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(17)30092-X – volume: 11 start-page: 510 year: 1994 ident: 10.1016/j.diabet.2019.101117_bib0305 article-title: Guidelines for encouraging psychological well-being: report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes publication-title: Diabet Med doi: 10.1111/j.1464-5491.1994.tb00316.x – volume: 19 start-page: 1155 year: 2017 ident: 10.1016/j.diabet.2019.101117_bib0175 article-title: Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA publication-title: Diabetes Obes Metab doi: 10.1111/dom.12927 – volume: 36 start-page: 1384 year: 2013 ident: 10.1016/j.diabet.2019.101117_bib0300 article-title: Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society publication-title: Diabetes Care doi: 10.2337/dc12-2480 – volume: (Suppl. 1) 42 start-page: S90 year: 2019 ident: 10.1016/j.diabet.2019.101117_bib0180 article-title: 9. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes – 2019 publication-title: Diabetes Care doi: 10.2337/dc19-S009 – volume: 61 start-page: 2461 year: 2018 ident: 10.1016/j.diabet.2019.101117_bib0185 article-title: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) publication-title: Diabetologia doi: 10.1007/s00125-018-4729-5 – volume: 6 start-page: 275 year: 2018 ident: 10.1016/j.diabet.2019.101117_bib0260 article-title: Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(18)30024-X – ident: 10.1016/j.diabet.2019.101117_bib0310 – volume: 7 start-page: 411 year: 2016 ident: 10.1016/j.diabet.2019.101117_bib0265 article-title: Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review publication-title: Diabetes Ther doi: 10.1007/s13300-016-0180-0 – volume: 55 start-page: 1577 year: 2012 ident: 10.1016/j.diabet.2019.101117_bib0280 article-title: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) publication-title: Diabetologia doi: 10.1007/s00125-012-2534-0 – volume: 394 start-page: 131 year: 2019 ident: 10.1016/j.diabet.2019.101117_bib0205 article-title: Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(19)31150-X – year: 2017 ident: 10.1016/j.diabet.2019.101117_bib0230 – volume: 8 start-page: 728 year: 2012 ident: 10.1016/j.diabet.2019.101117_bib0210 article-title: GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2012.140 – volume: 103 start-page: 2291 year: 2018 ident: 10.1016/j.diabet.2019.101117_bib0255 article-title: Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2018-00070 – volume: 58 start-page: 7370 year: 2015 ident: 10.1016/j.diabet.2019.101117_bib0320 article-title: Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide publication-title: J Med Chem doi: 10.1021/acs.jmedchem.5b00726 – volume: 5 start-page: 355 year: 2017 ident: 10.1016/j.diabet.2019.101117_bib0250 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(17)30085-2 – volume: 381 start-page: 117 year: 2013 ident: 10.1016/j.diabet.2019.101117_bib0340 article-title: Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study publication-title: Lancet doi: 10.1016/S0140-6736(12)61267-7 – volume: 53 start-page: 894 year: 2011 ident: 10.1016/j.diabet.2019.101117_bib0315 article-title: Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests publication-title: Biom J doi: 10.1002/bimj.201000239 – volume: (Suppl. 1) 21 start-page: 1 year: 2015 ident: 10.1016/j.diabet.2019.101117_bib0295 article-title: American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015 publication-title: Endocrine Practice doi: 10.4158/EP15672.GLSUPPL – volume: 375 start-page: 311 year: 2016 ident: 10.1016/j.diabet.2019.101117_bib0195 article-title: Liraglutide and cardiovascular outcomes in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1603827 – volume: 20 start-page: 254 year: 2016 ident: 10.1016/j.diabet.2019.101117_bib0215 article-title: Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future publication-title: Indian J Endocrinol Metab doi: 10.4103/2230-8210.176351 – volume: 310 start-page: 2191 year: 2013 ident: 10.1016/j.diabet.2019.101117_bib0275 article-title: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects publication-title: JAMA doi: 10.1001/jama.2013.281053 – volume: 377 start-page: 839 year: 2017 ident: 10.1016/j.diabet.2019.101117_bib0200 article-title: Liraglutide and renal outcomes in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1616011 – volume: 375 start-page: 1834 year: 2016 ident: 10.1016/j.diabet.2019.101117_bib0190 article-title: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1607141 – volume: 41 start-page: 258 year: 2018 ident: 10.1016/j.diabet.2019.101117_bib0245 article-title: Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial publication-title: Diabetes Care doi: 10.2337/dc17-0417 – ident: 10.1016/j.diabet.2019.101117_bib0270 – year: 2018 ident: 10.1016/j.diabet.2019.101117_bib0225 – volume: 58 start-page: 429 year: 2015 ident: 10.1016/j.diabet.2019.101117_bib0285 article-title: Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes publication-title: Diabetologia doi: 10.1007/s00125-014-3460-0 – volume: 384 start-page: 1349 year: 2014 ident: 10.1016/j.diabet.2019.101117_bib0335 article-title: Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(14)60976-4 – volume: 9 start-page: 1233 year: 2018 ident: 10.1016/j.diabet.2019.101117_bib0325 article-title: A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving basal insulin publication-title: Diabetes Ther doi: 10.1007/s13300-018-0428-y – volume: 44 start-page: 193 year: 2018 ident: 10.1016/j.diabet.2019.101117_bib0220 article-title: GLP-1 receptor agonists and cardiovascular protection: a class effect or not? publication-title: Diabetes Metab doi: 10.1016/j.diabet.2017.12.009 – volume: 9 start-page: 1149 year: 2018 ident: 10.1016/j.diabet.2019.101117_bib0330 article-title: A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving 1–2 oral anti-diabetic drugs publication-title: Diabetes Ther doi: 10.1007/s13300-018-0424-2 |
| SSID | ssj0012938 |
| Score | 2.6462855 |
| SourceID | crossref |
| SourceType | Enrichment Source Index Database |
| StartPage | 100 |
| Title | Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) |
| Volume | 46 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtNAEF6FVkJcEL-i_GkOHECWLa_XcexjVFqVQCpEEqm3aL1eh0T5qRKnSJx4Bx6Ex-HOkzDjtZ2FQkW5WNFmsrI9X2ZnZr-ZZexFSB0LwiRyIxmnbpgFiSvRq3YV16pNHcXyiAqc-6fRySjsnbXPWq3vFmtpW6Se-vzHupL_0SqOoV6pSvYamm0mxQH8jPrFK2oYr_-k4yPq_0DntZfZb5lrQ6-gSkT3U9kq39nohZzQPWTa4Z7vLCbOxcZIZJJSG_Pp2hIISEBSo6fMpW2ElcNrOoQQTlnNj6qYmoztVDnZejspGbWbbToriSF_S-wORoNh982pw_06-VC5xK93QhEdaI2onNd9DcvNkXP9cVVRjr2BtxsvMMwvDVXXc_vN-PF2XVPWet7bZrgnlyZX3vXsREfgW_wYY5uDKHBFZPql1Ma7yl9OrRjaWGLu-9aizsseDJfXC5O6mHnmfRDTL6FBbupJf23P_duy2ZAZa57cbGxmGdMsYzPLDbYfYPyCBni_e_jh3ftmgwu9rLJKs36muqqzpB5evhvLa7Lcn-EddruKW6BrQHiXtfTyHrvZr5gZ99m3GouAWASDRVjlYGERLCwCYhEWE7jYwA6LYGERBQISkBswWIRiBfzHl68CCIVgoxBKFMJ0CTUKgVAIhEIIoEYhvKwwCNx_9YCNjo-GhydudRiIq9AFL9CMRLEUWvvcl9QTMtVRlAaZkHlbZDF-qxKiLOs8FGhiVDsPlQhiGWehrzDGVuIh21uulvoRg5iCojgUuqNTikfSTHRUInne0TnXiTxgon7ZY1V1yqcDW-bjq1R9wNzmV-emU8yV8o-vKf-E3dr9K56yvWK91c_QIS7S5xW4fgIHebE0 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+safety+of+once-weekly+semaglutide+1.0+mg+vs+once-daily+liraglutide+1.2+mg+as+add-on+to+1%E2%80%933+oral+antidiabetic+drugs+in+subjects+with+type+2+diabetes+%28SUSTAIN+10%29&rft.jtitle=Diabetes+%26+metabolism&rft.au=Capehorn%2C+M.S.&rft.au=Catarig%2C+A.-M.&rft.au=Furberg%2C+J.K.&rft.au=Janez%2C+A.&rft.date=2020-04-01&rft.issn=1262-3636&rft.volume=46&rft.issue=2&rft.spage=100&rft.epage=109&rft_id=info:doi/10.1016%2Fj.diabet.2019.101117&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_diabet_2019_101117 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1262-3636&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1262-3636&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1262-3636&client=summon |